RxDoctor Payments Data

Ramzi Khalil, MD

Interventional Cardiology · Pittsburgh, PANPI 1790777829

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Edwards Lifesciences at 33.1% of the total. Reporting peaked in 2019 at $55,530 and has fallen 71.4% since, to $15,876 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$216,720in general payments, 2019–2025

Across 1,167 payments — averaging $185.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$72K
  • Johnson & Johnson$65K
  • Medtronic$34K
  • AstraZeneca$31K
  • Inari Medical, Inc.$3K
  • Boston Scientific$2K
  • plus $11K from 39 others
$1,387,757in research payments, 2019–2025

Across 205 payments — averaging $6769.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$752K
  • Edwards Lifesciences$586K
  • Abbott$49K
  • AstraZeneca$750

What the payments were for

  • Consulting fees$58,76127%
  • Speaking & faculty fees$104,63048%
  • Travel & lodging$13,7886%
  • Food & beverage$39,43718%
  • Education$1040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,720 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,825
Medicare patients
849
Services billed
1,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$191,150
EntrestoSacubitril/Valsartan105$102,329
XareltoRivaroxaban69$66,218
BrilintaTicagrelor48$33,868
Repatha SureclickEvolocumab39$21,040
JardianceEmpagliflozin15$7,849
Metoprolol Succinate396$5,698
Ranolazine ErRanolazine69$5,217
Valsartan157$4,877
Isosorbide Mononitrate ErIsosorbide Mononitrate156$3,718
Amiodarone Hcl41$3,528
Ezetimibe125$3,325
Atorvastatin Calcium223$3,068
Bumetanide67$2,449
Rosuvastatin Calcium149$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$191,150221 claims
NovartisEntresto$864$102,329105 claims
Johnson & JohnsonXarelto$64,627$66,21869 claims
AstraZenecaBrilinta$30,929$33,86848 claims
Boehringer IngelheimJardiance$95$7,84915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →